Can Fite Biopharma Ltd (CANF) - Net Assets
Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has net assets worth ILA5.59 Million ILA (≈ $14.99K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA9.51 Million ≈ $25.51K USD) and total liabilities (ILA3.92 Million ≈ $10.51K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CANF financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA5.59 Million |
| % of Total Assets | 58.78% |
| Annual Growth Rate | 4.62% |
| 5-Year Change | -61.11% |
| 10-Year Change | 44.37% |
| Growth Volatility | 75.86 |
Can Fite Biopharma Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Can Fite Biopharma Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Can Fite Biopharma Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Can Fite Biopharma Ltd (2003–2025)
The table below shows the annual net assets of Can Fite Biopharma Ltd from 2003 to 2025. For live valuation and market cap data, see CANF market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA5.59 Million ≈ $15.00K |
+2.89% |
| 2024-12-31 | ILA5.44 Million ≈ $14.57K |
-12.93% |
| 2023-12-31 | ILA6.24 Million ≈ $16.74K |
+39.60% |
| 2022-12-31 | ILA4.47 Million ≈ $11.99K |
-68.91% |
| 2021-12-31 | ILA14.38 Million ≈ $38.56K |
+136.78% |
| 2020-12-31 | ILA6.07 Million ≈ $16.28K |
+148.73% |
| 2019-12-31 | ILA2.44 Million ≈ $6.55K |
-19.00% |
| 2018-12-31 | ILA3.02 Million ≈ $8.08K |
-1.27% |
| 2017-12-31 | ILA3.05 Million ≈ $8.19K |
-21.17% |
| 2016-12-31 | ILA3.87 Million ≈ $10.39K |
-62.91% |
| 2015-12-31 | ILA10.44 Million ≈ $28.00K |
+52.33% |
| 2014-12-31 | ILA6.86 Million ≈ $18.38K |
+53.81% |
| 2013-12-31 | ILA4.46 Million ≈ $11.95K |
+729.67% |
| 2012-12-31 | ILA-707.99K ≈ $-1.90K |
-121.51% |
| 2011-12-31 | ILA3.29 Million ≈ $8.82K |
-74.82% |
| 2010-12-31 | ILA13.07 Million ≈ $35.05K |
-3.07% |
| 2009-12-31 | ILA13.49 Million ≈ $36.16K |
-8.84% |
| 2008-12-31 | ILA14.79 Million ≈ $39.66K |
-61.78% |
| 2007-12-31 | ILA38.70 Million ≈ $103.76K |
+0.95% |
| 2006-12-31 | ILA38.34 Million ≈ $102.79K |
+7.01% |
| 2005-12-31 | ILA35.83 Million ≈ $96.06K |
+2082.79% |
| 2004-12-31 | ILA-1.81 Million ≈ $-4.84K |
-187.34% |
| 2003-12-31 | ILA2.07 Million ≈ $5.55K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Can Fite Biopharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17622557500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | ILA1.13 Million | 20.15% |
| Other Components | ILA180.69 Million | 3230.58% |
| Total Equity | ILA5.59 Million | 100.00% |
Can Fite Biopharma Ltd Competitors by Market Cap
The table below lists competitors of Can Fite Biopharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shiva Mills Limited
NSE:SHIVAMILLS
|
$6.00 Million |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
$6.00 Million |
|
CPI Computer Peripherals International
AT:CPI
|
$6.00 Million |
|
Kandal M Venture Limited Class A Ordinary Shares
NASDAQ:FMFC
|
$6.01 Million |
|
Carlin Gold Corporation
V:CGD
|
$6.00 Million |
|
Bang Overseas Limited
NSE:BANG
|
$5.99 Million |
|
ISE Commerce Company Limited
KQ:069920
|
$5.98 Million |
|
ScandiDos AB
ST:SDOS
|
$5.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Can Fite Biopharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,436,000 to 5,593,160, a change of 157,160 (2.9%).
- Net loss of 10,638,522 reduced equity.
- New share issuances of 9,644,000 increased equity.
- Other comprehensive income increased equity by 233.
- Other factors increased equity by 1,151,449.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-10.64 Million | -190.21% |
| Share Issuances | ILA9.64 Million | +172.42% |
| Other Comprehensive Income | ILA233.00 | +0.0% |
| Other Changes | ILA1.15 Million | +20.59% |
| Total Change | ILA- | 2.89% |
Book Value vs Market Value Analysis
This analysis compares Can Fite Biopharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 153.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 346.90x to 153.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | ILA1.50 | ILA522.00 | x |
| 2011-12-31 | ILA0.29 | ILA522.00 | x |
| 2012-12-31 | ILA-0.12 | ILA522.00 | x |
| 2013-12-31 | ILA0.28 | ILA522.00 | x |
| 2014-12-31 | ILA0.37 | ILA522.00 | x |
| 2015-12-31 | ILA0.45 | ILA522.00 | x |
| 2016-12-31 | ILA0.14 | ILA522.00 | x |
| 2017-12-31 | ILA0.09 | ILA522.00 | x |
| 2018-12-31 | ILA0.08 | ILA522.00 | x |
| 2019-12-31 | ILA0.03 | ILA522.00 | x |
| 2020-12-31 | ILA0.02 | ILA522.00 | x |
| 2021-12-31 | ILA0.03 | ILA522.00 | x |
| 2022-12-31 | ILA0.01 | ILA522.00 | x |
| 2023-12-31 | ILA0.00 | ILA522.00 | x |
| 2024-12-31 | ILA0.00 | ILA522.00 | x |
| 2025-12-31 | ILA3.39 | ILA522.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Can Fite Biopharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -190.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2426.67%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.70x
- Recent ROE (-190.21%) is below the historical average (-170.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -28.13% | -493.50% | 0.04x | 1.42x | ILA-4.98 Million |
| 2011 | -247.42% | -1428.52% | 0.10x | 1.81x | ILA-6.97 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-5.45 Million |
| 2013 | -219.64% | 0.00% | 0.00x | 1.75x | ILA-8.72 Million |
| 2014 | -94.13% | 0.00% | 0.00x | 1.57x | ILA-6.75 Million |
| 2015 | -46.50% | -2912.29% | 0.01x | 1.71x | ILA-5.83 Million |
| 2016 | -178.44% | -4069.33% | 0.02x | 2.63x | ILA-7.28 Million |
| 2017 | -162.70% | -588.18% | 0.11x | 2.56x | ILA-5.27 Million |
| 2018 | -217.94% | -172.02% | 0.48x | 2.64x | ILA-6.87 Million |
| 2019 | -516.99% | -621.31% | 0.25x | 3.35x | ILA-12.87 Million |
| 2020 | -237.78% | -1892.92% | 0.08x | 1.57x | ILA-15.05 Million |
| 2021 | -87.57% | -1476.55% | 0.04x | 1.41x | ILA-14.03 Million |
| 2022 | -227.48% | -1255.93% | 0.09x | 2.08x | ILA-10.62 Million |
| 2023 | -122.28% | -1027.46% | 0.07x | 1.60x | ILA-8.26 Million |
| 2024 | -144.96% | -1169.14% | 0.07x | 1.68x | ILA-8.42 Million |
| 2025 | -190.21% | -2426.67% | 0.05x | 1.70x | ILA-11.20 Million |
Industry Comparison
This section compares Can Fite Biopharma Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $140,760,778
- Average return on equity (ROE) among peers: -44.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Can Fite Biopharma Ltd (CANF) | ILA5.59 Million | -28.13% | 0.70x | $6.00 Million |
| BioLine RX Ltd (BLRX) | $52.88 Million | -46.05% | 0.15x | $11.90 Million |
| BioLight Life Sciences Ltd (BOLT) | $8.03 Million | -214.92% | 2.08x | $6.79 Million |
| Bonus Biogroup (BONS) | $-6.38 Million | 0.00% | 0.00x | $129.32 Million |
| Clal Biotechnology Industries Ltd (CBI) | $1.11 Billion | 7.88% | 0.13x | $14.21 Million |
| Compugen (CGEN) | $17.67 Million | -77.12% | 0.64x | $197.75 Million |
| DNA Biomed Solns (DNA) | $579.00K | 0.00% | 15.68x | $38.30 Million |
| Enlivex Therapeutics Ltd (ENLV) | $30.67 Million | -22.89% | 0.07x | $519.31K |
| Evogene (EVGN) | $63.42 Million | -48.01% | 0.20x | $5.42 Million |
| Kadimastem Ltd (KDST) | $-8.56 Million | 0.00% | 0.00x | $22.18 Million |
About Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more